• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Microbiol Spectr . Revisiting endothelial tropism of SARS-CoV-2 using a cell-specific hACE2 mouse model

tetano

Editor, Senior Moderator
Microbiol Spectr


. 2026 Aug 11:e0131126.
doi: 10.1128/spectrum.01311-26. Online ahead of print.
Revisiting endothelial tropism of SARS-CoV-2 using a cell-specific hACE2 mouse model

Sahine Lameire[SUP] #[/SUP][SUP] 1 2 [/SUP], Nincy Debeuf[SUP] #[/SUP][SUP] 1 2 [/SUP], Julie Deckers[SUP] 1 2 [/SUP], Caroline De Wolf[SUP] 1 2 [/SUP], Manon Vanheerswynghels[SUP] 1 2 [/SUP], Wendy Toussaint[SUP] 1 2 [/SUP], Lize De Vlieger[SUP] 3 4 [/SUP], Lien Van Hoecke[SUP] 3 4 [/SUP], Arnout Bruggeman[SUP] 3 4 5 [/SUP], Sieglinde De Cae[SUP] 6 7 [/SUP], Bert Schepens[SUP] 6 7 [/SUP], Stijn Vanhee[SUP] 1 2 8 [/SUP], Bart N Lambrecht[SUP] 1 2 9 [/SUP]


Affiliations
Free article Abstract

Severe COVID-19 is frequently associated with vascular complications, raising ongoing debate about whether SARS-CoV-2 can directly infect endothelial cells and thereby contribute to disease pathogenesis. Although endothelial cells express angiotensin-converting enzyme 2 (ACE2), the in vivo relevance of endothelial-restricted viral tropism remains unclear. To directly assess the consequences of endothelial-restricted SARS-CoV-2 tropism in vivo, we generated a transgenic mouse model expressing human ACE2 under control of the endothelial-specific Cdh5 promoter (Cdh5-hACE2). Despite confirmed pulmonary endothelial expression and protein presence of hACE2, SARS-CoV-2 infection of Cdh5-hACE2 mice did not induce clinical illness, detectable viral replication, immune cell influx in the lung, or histopathological abnormalities in the lung or brain. These findings indicate that endothelial-restricted SARS-CoV-2 tropism alone is insufficient to drive productive infection and clinical disease in vivo, suggesting that endothelial involvement in COVID-19 likely arises in the context of broader cellular infection or systemic host responses rather than from primary endothelial infection.
Importance: Although SARS-CoV-2 primarily infects the upper and lower airways, COVID-19 was quickly recognized as a multi-organ disease, in which vascular complications are a recurring feature. This has raised the possibility that direct infection of endothelial cells contributes to disease pathogenesis. However, whether vascular injury arises from productive endothelial infection or instead represents a secondary consequence of systemic inflammation remains unresolved. To directly disentangle these possibilities and define the in vivo consequences of endothelial-restricted viral tropism, we generated a transgenic mouse model expressing human ACE2 under the control of the endothelial-specific Cdh5 promoter (Cdh5-hACE2).

Keywords: coronavirus; endothelial dysfunction; immunology; mouse model; viral tropism.

 
Back
Top